Abstract 1571
Background
Papillary carcinoma is the most common type of thyroid cancer and if it is not treated early, it can spread throughout the body. Therefore, the first line of treatment for papillary thyroid cancer is the surgery by removing part of or the entire thyroid. Our study aims to establish the most effective surgical procedure (total thyroidectomy or partial thyroidectomy) to achieve better survival for stage I and II papillary carcinoma and evaluate the effect of the ethnicity, sex and age on patients' survival undergoing these surgical techniques.
Methods
We extracted the data from the Surveillance, Epidemiology, and End Results (SEER) 18 registries. We retrieved data of 3691 patients diagnosed with papillary thyroid cancer in 2010. We evaluated the 5-year overall survival of patients using the log-rank test. Patients were grouped into two groups. The first one underwent thyroid lobectomy (242) and the second underwent total thyroidectomy (3449). Patients were further grouped according to ethnicity (white, black, American or Asian), sex (female or male) and age group.
Results
We found that total thyroidectomy was associated with better 5-year overall survival rates in patients with early stage papillary carcinoma, compared to lobectomy (98.1% and 96.5%, respectively, P = 0.021). Moreover, total thyroidectomy showed better survival rates in females than males (98.6% and 95.7%, respectively, p = 0.000) and in young patients aged between 20-39 years (99.8%, p = 0.000). Meanwhile, surgical techniques were not significantly associated with patients’ ethnicity.
Conclusions
Total thyroidectomy was superior to lobectomy in early stages papillary thyroid carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sara Ahmed.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract